IRIS
PELAIA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.274
AS - Asia 2.638
EU - Europa 1.330
SA - Sud America 937
Continente sconosciuto - Info sul continente non disponibili 248
AF - Africa 91
OC - Oceania 9
Totale 8.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.145
SG - Singapore 1.050
IT - Italia 716
BR - Brasile 714
CN - Cina 500
VN - Vietnam 450
IN - India 220
DE - Germania 168
HK - Hong Kong 133
AR - Argentina 89
GB - Regno Unito 82
BD - Bangladesh 76
FI - Finlandia 76
CA - Canada 56
NL - Olanda 48
MX - Messico 46
SE - Svezia 43
EC - Ecuador 42
ID - Indonesia 42
ES - Italia 31
IQ - Iraq 28
RU - Federazione Russa 28
FR - Francia 27
CO - Colombia 24
ZA - Sudafrica 23
VE - Venezuela 21
UA - Ucraina 20
TR - Turchia 17
AT - Austria 16
EG - Egitto 16
PY - Paraguay 16
PE - Perù 13
PL - Polonia 13
MA - Marocco 12
NP - Nepal 11
PK - Pakistan 11
CZ - Repubblica Ceca 10
IE - Irlanda 10
JP - Giappone 10
TW - Taiwan 10
CL - Cile 9
DO - Repubblica Dominicana 9
AU - Australia 8
KE - Kenya 8
MY - Malesia 8
PH - Filippine 8
SA - Arabia Saudita 8
TN - Tunisia 8
UY - Uruguay 8
IL - Israele 7
AE - Emirati Arabi Uniti 6
TH - Thailandia 6
UZ - Uzbekistan 6
DZ - Algeria 5
ET - Etiopia 5
JO - Giordania 5
CH - Svizzera 4
CR - Costa Rica 4
EE - Estonia 4
IR - Iran 4
LT - Lituania 4
LV - Lettonia 4
PT - Portogallo 4
RO - Romania 4
SC - Seychelles 4
AL - Albania 3
BG - Bulgaria 3
JM - Giamaica 3
KG - Kirghizistan 3
KR - Corea 3
KZ - Kazakistan 3
LB - Libano 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
CG - Congo 2
GR - Grecia 2
HN - Honduras 2
NG - Nigeria 2
OM - Oman 2
PA - Panama 2
TT - Trinidad e Tobago 2
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
EU - Europa 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
KI - Kiribati 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
MR - Mauritania 1
NE - Niger 1
Totale 8.275
Salva come PNG Salva come JPEG
Città #
San Jose 659
Singapore 399
Dallas 377
Ashburn 312
Santa Clara 205
Ho Chi Minh City 194
Chandler 179
Bengaluru 164
Hefei 160
Council Bluffs 149
Hong Kong 127
Beijing 104
Munich 103
Hanoi 89
Milan 79
Princeton 68
Lawrence 67
São Paulo 65
Chicago 62
Turku 52
Catanzaro 48
London 47
Los Angeles 43
Wilmington 42
Boardman 38
Naples 37
Rome 37
Haiphong 28
Palermo 27
New York 25
Florence 22
Orem 22
Helsinki 21
Quito 21
Rio de Janeiro 19
Des Moines 18
Mexico City 18
San Nicola Manfredi 18
San Francisco 16
Thái Bình 16
Amsterdam 15
Biên Hòa 15
Brooklyn 15
Johannesburg 15
Ninh Bình 15
Baghdad 14
Bari 13
Guayaquil 13
Porto Alegre 13
Brasília 12
Buenos Aires 12
Redwood City 12
Warsaw 12
Alessandria 11
Belo Horizonte 11
Catania 11
Chennai 11
Troina 11
Curitiba 10
Olomouc 10
Paris 10
Redmond 10
Salvador 10
Seattle 10
Denver 9
Guarulhos 9
Lima 9
Montreal 9
Norwalk 9
Ottawa 9
Atlanta 8
Boston 8
Buffalo 8
Dublin 8
Galbiate 8
Hải Dương 8
Mascalucia 8
Messina 8
Thái Nguyên 8
Tokyo 8
Toronto 8
Asunción 7
Da Nang 7
Hanover 7
Montevideo 7
Mumbai 7
Nairobi 7
Reggio Emilia 7
Taipei 7
The Dalles 7
Ankara 6
Bangkok 6
Bogotá 6
Can Tho 6
Castrovillari 6
Caxias do Sul 6
Columbus 6
Frankfurt am Main 6
Manaus 6
Manchester 6
Totale 4.733
Salva come PNG Salva come JPEG
Nome #
Patient-derived 3D nasal spheroids reveal epithelial changes following Dupilumab therapy in CRSwNP: a preliminary report 159
25-Hydroxy Vitamin D Detection Using Different Analytic Methods in Patients with Migraine 126
Arg16Gly 132-Adrenoreceptor Polymorphism in Severe Eosinophilic Asthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission 101
An Analytical Method for Assessing Optimal Storage Conditions of Gingival Crevicular Fluid and Disclosing a Peptide Biomarker Signature of Gingivitis by MALDI-TOF MS 100
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study 92
Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma 84
High-flow nasal cannula oxygen therapy for outpatients undergoing flexible bronchoscopy: a randomised controlled trial 83
Evaluation of a New Interface Combining High-Flow Nasal Cannula and CPAP 78
Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children 78
Type 2 severe asthma: pathophysiology and treatment with biologics 77
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission 77
Uric acid and vascular damage in essential hypertension: Role of insulin resistance 77
Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma 76
Rapid detection and identification of antimicrobial peptide fingerprints of nasal fluid by mesoporous silica particles and MALDI-TOF/TOF mass spectrometry: from the analytical approach to the diagnostic applicability in precision medicine 73
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study 72
New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant 71
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy 70
Association Between Sleep Apnea and Valvular Heart Diseases 70
Real-World Evaluation of Dupilumab in the Long-Term Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-4 and IL-13 Receptor Blockade 69
MALDI MS-Based Investigations Targeting SARS-CoV-2 67
Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea 66
Device for Performing Spirometry in Total Laryngectomized Patients 66
Benefits of secretion clearance with high frequency percussive ventilation in tracheostomized critically ill patients: a pilot study 66
Clinical remission in severe asthma: lights and shadows on an ambitious goal 66
Hexagonal Mesoporous Silica as a Rapid, Efficient and Versatile Tool for MALDI-TOF MS Sample Preparation in Clinical Peptidomics Analysis: A Pilot Study. 66
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis 65
Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis 65
An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD 65
Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients 63
Nasal polyposis: Insights in epithelial-mesenchymal transition and differentiation of polyp mesenchymal stem cells 63
Assessment of cephalometric parameters and correlation with the severity of the obstructive sleep apnea syndrome 62
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 62
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose 62
Current Practice of High Flow through Nasal Cannula in Exacerbated COPD Patients 62
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence 62
Recognizing, quantifying and managing patient-ventilator asynchrony in invasive and noninvasive ventilation. 61
Comparisons of two diaphragm ultrasound-teaching programs: a multicenter randomized controlled educational study. 60
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets 59
Emerging biological treatments for asthma 59
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab 58
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 58
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma 57
Effect of continuous positive airway pressure on non-fatal stroke and paroxysmal atrial fibrillation recurrence in obstructive sleep apnoea elderly patients 57
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role 56
Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients 56
Nurse led protocols for control of glycaemia in critically ill patients: A systematic review 56
Biologics in severe asthma 56
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study 55
Tissue microRNA dynamics in sinonasal inverted papilloma: implications for pathology and therapy 55
Imaging of chronic rhinosinusitis with nasal polyps in the era of biological therapies 55
Oxygenation strategies during flexible bronchoscopy: a review of the literature 55
Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease 55
Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury 55
What is the Role of Sex-Related Differences in the Effectiveness and Safety of Biological Drugs used in Patients' Severe Asthma? 54
Switching Biological Therapies in Severe Asthma 54
Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers 54
Maxillary sinus mucocele with orbital complications 54
Gingival Crevicular Fluid Peptidome Profiling in Healthy and in Periodontal Diseases. 54
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma 54
Fluid Challenge During Anesthesia: A Systematic Review and Meta-analysis. 53
Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study 53
Mapping the SARS-CoV-2–host protein–protein interactome by affinity purification mass spectrometry and proximity-dependent biotin labeling: A rational and straightforward route to discover host-directed anti-SARS-CoV-2 therapeutics 53
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 53
Patient-ventilator asynchrony in adult critically ill patients 53
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 51
Allergy clinics in times of the SARS-CoV-2 pandemic: An integrated model 51
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness 51
Clinical relevance of understanding mitogen-activated protein kinases involved in asthma 51
Phenotyping severe asthma: a rationale for biologic therapy 51
Asthma control during COVID-19 lockdown in patients with severe asthma under biological drug treatment 51
Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (Copd): A multicenter observational study 51
Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study 50
Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis 50
Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study 50
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis 50
Adherence to omalizumab: A multicenter “real-world” study 50
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study 50
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine 49
Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics 49
Effects of continuous positive airway pressure on comprehensive geriatric assessment and cognitive function in elderly patients with obstructive sleep apnea syndrome 49
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy 49
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype 49
Interleukin-5 in the Pathophysiology of Severe Asthma 49
Primary mucosal melanoma presenting with a unilateral nasal obstruction of the left inferior turbinate 49
Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: A real-life experience from Southern Italy 49
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting 48
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma 48
Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma 48
Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma 47
Effect of SGLT2-Inhibitors on Polygraphic Parameters in Elderly Patients Affected by Heart Failure, Type 2 Diabetes Mellitus, and Sleep Apnea 47
Intrinsic laryngeal lipoma treated with transoral Co2 laser microsurgery: An unusual case report 47
Tezepelumab: A potential new biological therapy for severe refractory asthma 47
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab 46
Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease 46
Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy 46
Cost-Sensitive Models to Predict Risk of Cardiovascular Events in Patients with Chronic Heart Failure 46
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma 46
Influence of allergic status and nasal polyposis on long-term Benralizumab response in eosinophilic severe asthma 46
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience 46
Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-allergic phenotype expression 46
Totale 6.022
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.618
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022237 0 5 33 34 7 8 22 40 29 22 36 1
2022/2023625 141 33 41 25 61 56 26 54 85 30 52 21
2023/2024390 68 46 34 28 13 76 6 18 6 26 24 45
2024/20251.637 169 19 27 34 190 215 109 50 164 52 254 354
2025/20265.119 237 494 773 1.012 465 232 541 245 542 361 118 99
2026/2027303 81 222 0 0 0 0 0 0 0 0 0 0
Totale 8.527